Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionVictory Capital Management Inc
Latest Disclosed Ownership1,888,521 shares
Latest Disclosed Value $ 843,328,237
Victory Capital Management Inc reports 43.74% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Victory Capital Management Inc filed a 13F-HR form disclosing ownership of 1,888,521 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $843,300,167 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 3,356,766 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -43.74% during the quarter. The current value of the position is $843,847,838 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,888,521 -1,468,245 -43.74 843,328 -44.59 0.4049
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,356,766 1,109,200 49.35 1,521,851 93.30 0.8588
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,247,566 92,402 4.29 787,317 -18.65 0.4604
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,155,164 1,861,279 633.34 967,777 579.23 0.6241
2025-05-02 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 293,885 -11,261 -3.69 142,481 15.95 0.1458
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 305,146 -5,268 -1.70 122,882 -14.88 0.1208
2024-11-05 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 310,414 -15,334 -4.71 144,367 -5.45 0.1391
2024-08-05 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 325,748 -81,906 -20.09 152,685 -10.40 0.1531
2024-05-03 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 407,654 -28,184 -6.47 170,403 -3.91 0.1664
2024-02-05 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 435,838 -142,613 -24.65 177,338 -11.84 0.1866
2023-11-06 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 578,451 81,615 16.43 201,151 15.05 0.2312
2023-07-27 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 496,836 -49,703 -9.09 174,842 1.53 0.1923
2023-05-02 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 546,539 51,149 10.32 172,198 20.37 0.1934
2023-04-25 2022-12-31 13F/A-3 VERTEX PHARMACEUTICALS COM 92532F100 495,390 -28,134 -5.37 143,059 -5.62 0.1646
2023-03-10 2022-12-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 495,390 -28,134 143,059 0.0987
2023-02-10 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 495,390 -28,134 143,059 0.0001
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 491,208 -32,316 148,224 0.1007
2022-11-02 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 523,524 -25,868 -4.71 151,581 -2.09 0.1769
2022-08-01 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 549,392 27,854 5.34 154,813 11.96 0.1764
2022-05-04 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 521,538 351,044 205.90 138,280 269.34 0.1383
2022-02-07 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 170,494 4,717 2.85 37,440 24.51 0.0344
2021-11-02 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 165,777 6,324 3.97 30,070 -6.47 0.0294
2021-08-03 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 159,453 -413,825 -72.19 32,151 -73.90 0.0309
2021-05-04 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 573,278 -83,922 -12.77 123,191 -20.69 0.1262
2021-02-01 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 657,200 104,471 18.90 155,323 3.27 0.1730
2020-11-09 2020-09-30 13F Vertex Pharmaceuticals COM 92532F100 552,729 -32,147 -5.50 150,408 -11.42 0.1931
2020-08-07 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 584,876 60,251 11.48 169,795 36.02 0.2299
2020-05-12 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 524,625 176,974 50.91 124,835 64.00 0.2093
2020-05-04 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 524,625 176,974 124,835 136,619.2222
2020-02-06 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 347,651 199,395 134.49 76,118 203.04 0.0924
2020-02-04 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 533,962 385,706 121,236 145,324.4592
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 148,256 129,162 676.45 25,118 617.45 0.0323
2019-08-15 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,094 67 0.35 3,501 0.03 0.0071
2019-05-03 2019-03-31 13F VERTEX PHARMACEUTICALS CS 92532F100 19,027 15,258 404.83 3,500 460.00 0.0080
2019-05-02 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 3,769 -25 -0.66 625 -14.50 0.0016
2019-02-05 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,769 -25 625
2018-11-01 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,794 -46 -1.20 731 11.94 0.0015
2018-08-02 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,840 -80 -2.04 653 2.19 0.0014
2018-05-04 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,920 -75 -1.88 639 6.68 0.0014
2018-02-01 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,995 -166 -3.99 599 -5.37 0.0013
2017-10-27 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,161 -130 -3.03 633 14.47 0.0014
2017-08-07 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,291 -229 -5.07 553 11.94 0.0013
2017-05-10 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,520 -144 -3.09 494 43.60 0.0012
2017-02-09 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,664 -67 -1.42 344 -16.71 0.0009
2016-11-02 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,731 1,574 49.86 413 51.84 0.0012
2016-08-09 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,157 -68 -2.11 272 6.25 0.0011
2016-05-17 2016-03-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 3,225 -85 -2.57 256 -38.46 0.0011
2016-05-12 2016-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 3,225 0 256 0.0011
2016-05-12 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,225 256
2016-02-10 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,310 3,310 0.00 416 0.0017
2015-11-06 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 0 0 0.0000
2014-02-12 2013-12-31 13F Vertex Pharmaceuticals Common Stock 92532F100 0 -4 -100.00 0 0.0000
2014-03-12 2013-09-30 13F/A-1 Vertex Pharmaceuticals Common Stock 92532F100 4 4 0 0.0000
2013-11-12 2013-09-30 13F Vertex Pharmaceuticals Common Stock 92532F100 4 0
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.